Capivasertib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient With Metastatic Prostate Cancer With Bone Involvement: A Case Report of a Rare but Serious Metabolic Complication.

Capivasertib, a protein kinase B (AKT) inhibitor manufactured by AstraZeneca pharmaceutical and used in the treatment of various malignancies, has been implicated in cases of drug-induced diabetic ketoacidosis (DKA). We present a case of capivasertib-induced DKA in a patient with no prior history of diabetes, highlighting the metabolic complications associated with this targeted therapy. The proposed mechanism involves AKT inhibition leading to impaired insulin signaling, reduced glucose uptake, and increased lipolysis, ultimately resulting in ketogenesis. This case underscores the need for vigilant glucose monitoring in patients receiving capivasertib, especially those with predisposing risk factors for insulin resistance or pancreatic dysfunction.